This is a working overview of GIP receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-17. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
This stratified squamous epithelium is maintained by cell division within the stratum basale, in which differentiating cells slowly displace outwards through the stratum spinosum to the stratum corneum, where cells are continually shed from the surface. In normal skin, the rate of production equals the rate of loss; about two weeks are needed for a cell to migrate from the basal cell layer to the top of the granular cell layer, and an additional two weeks to cross the stratum corneum. The dermis is the layer of skin between the epidermis and subcutaneous tissue, and comprises two sections, the papillary dermis and the reticular dermis. The superficial papillary dermis interdigitates with the overlying rete ridges of the epidermis, between which the two layers interact through the basement membrane zone. Structural components of the dermis are collagen, elastic fibers, and ground substance. Within these components are the pilosebaceous units, arrector pili muscles, and the eccrine and apocrine glands. The dermis contains two vascular networks that run parallel to the skin surface—one superficial and one deep plexus—which are connected by vertical communicating vessels. The function of blood vessels within the dermis is fourfold: to supply nutrition, to regulate temperature, to modulate inflammation, and to participate in wound healing. The subcutaneous tissue is a layer of fat between the dermis and underlying fascia.
=== Organoeinsteinium compounds === Einsteinium's high radioactivity has a potential use in radiation therapy, and organometallic complexes have been synthesized in order to deliver einsteinium to an appropriate organ in the body. Experiments have been performed on injecting einsteinium citrate (as well as fermium compounds) to dogs. Einsteinium(III) was also incorporated into β-diketone chelate complexes, since analogous complexes with lanthanides previously showed strongest UV-excited luminescence among metallorganic compounds. When preparing einsteinium complexes, the Es3+ ions were 1000 times diluted with Gd3+ ions. This allowed reducing the radiation damage so that the compounds did not disintegrate during the 20 minutes required for the measurements. The resulting luminescence from Es3+ was much too weak to be detected. This was explained by the unfavorable relative energies of the individual constituents of the compound that hindered efficient energy transfer from the chelate matrix to Es3+ ions. Similar conclusion was drawn for americium, berkelium and fermium. Luminescence of Es3+ ions was however observed in inorganic hydrochloric acid solutions as well as in organic solution with di(2-ethylhexyl)orthophosphoric acid. It shows a broad peak at about 1064 nanometers (half-width about 100 nm) which can be resonantly excited by green light (ca. 495 nm wavelength). The luminescence has a lifetime of several microseconds and the quantum yield below 0.1%.
Sanger retired in 1983, aged 65, to his home, "Far Leys", in Swaffham Bulbeck outside Cambridge. In 1992, the Wellcome Trust and the Medical Research Council founded the Sanger Centre (now the Sanger Institute), named after him. The institute is on the Wellcome Trust Genome Campus near Hinxton, only a few miles from Sanger's home. He agreed to having the Centre named after him when asked by John Sulston, the founding director, but warned, "It had better be good." It was opened by Sanger in person on 4 October 1993, with a staff of fewer than 50 people, and went on to take a leading role in the sequencing of the human genome. The Institute had about 900 people in 2020 and is one of the world's largest genomic research centres. Sanger said he found no evidence for a God so he became an agnostic. In an interview published in the Times newspaper in 2000 Sanger is quoted as saying: "My father was a committed Quaker and I was brought up as a Quaker, and for them truth is very important. I drifted away from those beliefs – one is obviously looking for truth, but one needs some evidence for it. Even if I wanted to believe in God I would find it very difficult. I would need to see proof." He declined the offer of a knighthood, as he did not wish to be addressed as "Sir". He is quoted as saying, "A knighthood makes you different, doesn't it, and I don't want to be different." In 1986 he accepted admission to the Order of Merit, which can have only 24 living members.
Sources: en.wikipedia.org
=== Medicine storage and usage by astronauts === Medication storage and on-site production have become crucial areas of research due to extensive periods away from Earth. Factors, such as shelf life and drug stability, on drug storage, are impacted due to the effects of radiation, long space flight durations, and microgravity. Current solutions aim at frequent missions to resupply and restock medicines and commonly used drugs, however, this is not possible for long-term spaceflight to Mars or other distant missions. In addition, due to the toll that spaceflight takes on the human body, medicine use by astronauts have been extensively studied. High rates of sleep medication are taken by astronauts to combat sleep deprivation, disturbances, and other sleep-related disorders caused by an increased presence of CO2 in the International Space Station. Medications for congestion and allergies, combined with headache-related medications, are also significantly used, primarily because of the cephalad fluid shifts caused by a transition to weightless environment.
Because a dalton, a unit commonly used to measure atomic mass, is exactly 1/12 of the mass of a carbon-12 atom, this definition of the mole entailed that the mass of one mole of a compound or element in grams was numerically equal to the average mass of one molecule or atom of the substance in daltons, and that the number of daltons in a gram was equal to the number of elementary entities in a mole. Because the mass of a nucleon (i.e. a proton or neutron) is approximately 1 dalton and the nucleons in an atom's nucleus make up the overwhelming majority of its mass, this definition also entailed that the mass of one mole of a substance was roughly equivalent to the number of nucleons in one atom or molecule of that substance. Since the definition of the gram was not mathematically tied to that of the dalton, the number of molecules per mole NA (the Avogadro constant) had to be determined experimentally. The experimental value adopted by CODATA in 2010 is NA = 6.02214129(27)×1023 mol−1. In 2011 the measurement was refined to 6.02214078(18)×1023 mol−1. The mole was made the seventh SI base unit in 1971 by the 14th CGPM.
=== Anticoagulant effects === 1-Methylnicotinamide is an endogenous activator of prostacyclin synthesis and can therefore regulate thrombolytic and inflammatory processes in the cardiovascular system. It inhibits platelet-dependent thrombosis through a mechanism involving cyclooxygenase-2 and prostacyclin (PGI2) and increases nitric oxide bioavailability in the endothelium. Endogenous prostacyclin (PGI2) plays a critical role in preventing platelet aggregation and thrombus formation. A deficiency in PGI2 can lead to increased platelet aggregation and arterial thrombi.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.